MX2013011589A - Metodos y composiciones para tratar enfermedad de parkinson. - Google Patents
Metodos y composiciones para tratar enfermedad de parkinson.Info
- Publication number
- MX2013011589A MX2013011589A MX2013011589A MX2013011589A MX2013011589A MX 2013011589 A MX2013011589 A MX 2013011589A MX 2013011589 A MX2013011589 A MX 2013011589A MX 2013011589 A MX2013011589 A MX 2013011589A MX 2013011589 A MX2013011589 A MX 2013011589A
- Authority
- MX
- Mexico
- Prior art keywords
- disease
- compositions
- methods
- treating parkinson
- treating
- Prior art date
Links
- 208000018737 Parkinson disease Diseases 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención describe métodos y composiciones para tratar o prevenir la enfermedad de Parkinson, administrando un compuesto de la Fórmula (I): o una sal, solvato o hidrato farmacéuticamente aceptable del mismo, en donde las variables son tal como se define en la presente invención.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161472961P | 2011-04-07 | 2011-04-07 | |
PCT/US2012/032544 WO2013101281A1 (en) | 2011-04-07 | 2012-04-06 | Methods and compositions for treating parkinson's disease |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2013011589A true MX2013011589A (es) | 2013-12-16 |
Family
ID=48698489
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013011589A MX2013011589A (es) | 2011-04-07 | 2012-04-06 | Metodos y composiciones para tratar enfermedad de parkinson. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20140066434A1 (es) |
EP (1) | EP2694066A1 (es) |
JP (1) | JP2014513078A (es) |
KR (1) | KR20140022062A (es) |
CN (1) | CN103596568A (es) |
AU (1) | AU2012363094A1 (es) |
BR (1) | BR112013024169A2 (es) |
CA (1) | CA2832465A1 (es) |
EA (1) | EA201391486A1 (es) |
MX (1) | MX2013011589A (es) |
WO (1) | WO2013101281A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3167093A1 (en) | 2012-12-12 | 2014-06-12 | Ariad Pharmaceuticals, Inc. | Crystalline form c of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-{4-[(4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride |
AU2013204506B2 (en) * | 2012-12-13 | 2016-05-05 | Ariad Pharmaceuticals, Inc. | Crystalline forms of 3-(imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide mono hydrochloride |
CN104341416B (zh) * | 2013-07-31 | 2017-03-29 | 南京圣和药业股份有限公司 | 蛋白酪氨酸激酶抑制剂及其应用 |
GB2518873A (en) * | 2013-10-03 | 2015-04-08 | Agency Science Tech & Res | Bicyclic alkyne derivatives and uses thereof |
EP3072964A1 (en) * | 2013-11-22 | 2016-09-28 | National Center For Child Health And Development | Novel chimera gene atf7ip-pdgfrb for acute lymphoblastic leukemia |
CN104650086A (zh) * | 2013-11-22 | 2015-05-27 | 天津市汉康医药生物技术有限公司 | 盐酸帕纳替尼化合物 |
WO2015085973A1 (en) * | 2013-12-09 | 2015-06-18 | Zentiva, K.S. | Modifications of 3-(2-imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-n-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl] benzamide hydrochloride salt |
CN104496940B (zh) * | 2014-01-06 | 2017-03-15 | 广东东阳光药业有限公司 | 一种制备bcr‑abl抑制剂中间体的方法 |
CN106146391A (zh) * | 2015-04-15 | 2016-11-23 | 中国科学院上海药物研究所 | 5-芳香炔基取代的苯甲酰胺类化合物及其制备方法、药物组合物和用途 |
WO2017222285A1 (ko) * | 2016-06-20 | 2017-12-28 | 재단법인 대구경북첨단의료산업진흥재단 | 신규한 이미다조피리딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
WO2020013531A1 (ko) * | 2018-07-10 | 2020-01-16 | 보로노이바이오 주식회사 | N-(3-(이미다조[1,2-b]피리다진-3-일에티닐)-4-메틸페닐)-5-페닐-4,5-다이하이드로-1H-피라졸-1-카복사마이드 유도체 및 이를 유효성분으로 포함하는 키나아제 관련 질환 치료용 약학적 조성물 |
EP3808746B1 (en) * | 2018-07-17 | 2023-08-02 | Shenzhen TargetRx, Inc. | N-[3-[2-[8-[(1h-pyrazol-4-yl)amino]imidazo[1,2-a]pyrazin-3-yl]ethynyl]phenyl]-benzamide derivatives and related compounds as protein kinase inhibitors for the treatment of cancer |
CA3133100A1 (en) | 2019-03-19 | 2020-09-24 | Boehringer Ingelheim Animal Health USA Inc. | Anthelmintic aza-benzothiophene and aza-benzofuran compounds |
WO2020214999A1 (en) * | 2019-04-17 | 2020-10-22 | Emory University | Abelson non-tyrosine kinase compounds for the treatment of neurodegenerative diseases |
CN111004240B (zh) * | 2019-12-13 | 2020-12-01 | 山东铂源药业有限公司 | 一种泊那替尼中间体3-乙炔基咪唑并[1,2-b]哒嗪的合成方法 |
WO2021172931A1 (ko) * | 2020-02-28 | 2021-09-02 | 재단법인 대구경북첨단의료산업진흥재단 | 3-((8-((1h-피라졸-4-일)아미노)이미다조[1,2-a]피리딘-3-일)에티닐)-n-페닐벤즈아미드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물 |
KR20230028268A (ko) | 2020-05-29 | 2023-02-28 | 뵈링거 잉겔하임 애니멀 헬스 유에스에이 인코포레이티드 | 구충성 헤테로시클릭 화합물 |
JP2024514015A (ja) | 2021-04-13 | 2024-03-27 | シェンツェン ニューデル バイオテック カンパニー リミテッド | アルキニルフェニルベンズアミド化合物およびその使用 |
EP4426699A1 (en) | 2021-11-01 | 2024-09-11 | Boehringer Ingelheim Vetmedica GmbH | Anthelmintic pyrrolopyridazine compounds |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6841567B1 (en) * | 1999-02-12 | 2005-01-11 | Cephalon, Inc. | Cyclic substituted fused pyrrolocarbazoles and isoindolones |
US20040198650A1 (en) * | 2001-03-29 | 2004-10-07 | Poul Jensen | Means for inhibiting proteolytical processing of parkin |
DE10360793A1 (de) * | 2003-12-23 | 2005-07-28 | Grünenthal GmbH | Spirocyclische Cyclohexan-Derivate |
CN101389338B (zh) * | 2005-12-23 | 2013-06-26 | 阿里亚德医药股份有限公司 | 双环杂芳基化合物 |
CN103044432B (zh) * | 2005-12-23 | 2016-08-03 | 阿里亚德医药股份有限公司 | 双环杂芳基化合物 |
-
2012
- 2012-04-06 CA CA2832465A patent/CA2832465A1/en not_active Abandoned
- 2012-04-06 US US14/009,511 patent/US20140066434A1/en not_active Abandoned
- 2012-04-06 JP JP2014504027A patent/JP2014513078A/ja active Pending
- 2012-04-06 MX MX2013011589A patent/MX2013011589A/es not_active Application Discontinuation
- 2012-04-06 AU AU2012363094A patent/AU2012363094A1/en not_active Abandoned
- 2012-04-06 CN CN201280027388.3A patent/CN103596568A/zh active Pending
- 2012-04-06 KR KR1020137029633A patent/KR20140022062A/ko not_active Application Discontinuation
- 2012-04-06 EP EP12861665.3A patent/EP2694066A1/en not_active Withdrawn
- 2012-04-06 EA EA201391486A patent/EA201391486A1/ru unknown
- 2012-04-06 WO PCT/US2012/032544 patent/WO2013101281A1/en active Application Filing
- 2012-04-06 BR BR112013024169A patent/BR112013024169A2/pt not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
JP2014513078A (ja) | 2014-05-29 |
CN103596568A (zh) | 2014-02-19 |
WO2013101281A1 (en) | 2013-07-04 |
EP2694066A1 (en) | 2014-02-12 |
AU2012363094A1 (en) | 2013-09-19 |
EA201391486A1 (ru) | 2014-09-30 |
US20140066434A1 (en) | 2014-03-06 |
BR112013024169A2 (pt) | 2016-12-06 |
CA2832465A1 (en) | 2013-07-04 |
KR20140022062A (ko) | 2014-02-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2013011589A (es) | Metodos y composiciones para tratar enfermedad de parkinson. | |
MX2013011591A (es) | Métodos y composiciones para tratar enfermedades neurodegenerativas. | |
MX2020010151A (es) | Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn. | |
MX2011011335A (es) | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamifero de rapamicina. | |
PH12019500480A1 (en) | Pyridine compound | |
MX2011009796A (es) | Inhibidores de la cinasa pi3. | |
MX2014001595A (es) | Compuestos de imidazol, composiciones y metodos de uso. | |
IN2014KN00948A (es) | ||
GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
MX2013007336A (es) | Compuestos de bi-heteroarilo como inhibidores de vps34. | |
MX2016001400A (es) | Derivados de piridazina 1,4-disustituida, y su uso para el tratamiento de afecciones relacionadas con la deficiencia de smn. | |
PH12018500061A1 (en) | Oxysterols and methods of use thereof | |
MX2020007023A (es) | Analogos detiadiazol y metodos para el tratamiento de afecciones relacionadas con la deficiencia del gen de supervivencia de las neuronas motoras (smn). | |
MX2020011449A (es) | Oxiesteroles y metodos de uso de los mismos. | |
WO2011127333A3 (en) | Compounds for treating disease, for administering, and for pharmaceutical compositions | |
JO3387B1 (ar) | مشتقات بيتولين | |
EP4316591A3 (en) | Oxysterols and methods of use thereof | |
NZ746825A (en) | Oxysterols and methods of use thereof | |
GEP20186880B (en) | 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease | |
MX2016008665A (es) | Derivado basado en 1,2-naftoquinona y metodo de preparacion del mismo. | |
MY167898A (en) | Co-crystals and salts of ccr3-inhibitors | |
WO2013040227A3 (en) | Therapeutic compounds | |
PH12015500111A1 (en) | Difluorolactam compositions for ep4-mediated osteo related diseases and conditions | |
MX341341B (es) | Derivados de benzamida y su uso como inhibidores de proteina de choque termico 90 kda (hsp90). | |
MX2014003701A (es) | Compuestos para el tratamiento y profilaxis de enfermedad por el virus sincitial respiratorio. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |